Piramal Pharma (NSE:PPLPHARMA, BOM:543635) has received an establishment inspection report from the US Food and Drug Administration (US FDA) after the inspection of its manufacturing facility at Digwal in Telangana, India, according to a filing to the Indian stock exchanges on Monday.
With this, the inspection has been successfully closed by the US FDA.
The company's shares were down nearly 1% in recent trade.